
Clinical PhaseWhen entering this most costly and exciting phase, make sure that you are working with real experts. We will champion your product and remain dedicated to the project until your medicine has reached the market and is benefiting patients. Average success rates from first-in-man to registration is 11%*. (*Reference 1) Mistakes in the clinical phase can be very costly. There are some critical issues to consider in the clinical phase which if ignored will be expensive in terms of time.
Can you provide evidence
that your product is cost-effective, knowing that post approval
you will face the 4th hurdle?
|
||||||||||
Take advantage of our knowledge and experience during this important phase of your product development. |
||||||||||
| *References 1. http://pipeline.corante.com/archives/2004/09/20/drug_development_the_current_odds.php and http://www.cs.princeton.edu/picasso/abstracts_F06/krishna_files/Kola-Landis2004.pdf |